

(Published in Part II, Section 3, Sub Section (ii) of the  
Gazette of India Extraordinary, dated the)

Government of India  
Ministry of Chemicals and Fertilizers  
Department of Pharmaceuticals  
(National Pharmaceuticals Pricing Authority)

New Delhi, the 31<sup>st</sup> July 2017

### CORRIGENDUM

S.O. 2422(E) - In the National Pharmaceutical Pricing Authority's notification S.O. 2402(E), dated 28<sup>th</sup> July, 2017, relating to the retail price fixation of Fusidic Acid + Mometasone Furoate (Bactrafuz – M cream), published in the Gazette of India, Extraordinary, of the Entry at Sl. No. 1 of the Table, both in Hindi & English version be read as follows :

Instead of

Sl. No.	Name of the Scheduled Formulation / Brand Name	Strength	Unit	Manufacturer & Marketing Company respectively	Retail Price (Rs.)
(1)	(2)	(3)	(4)	(5)	(6)
1.	Fusidic Acid + Mometasone Furoate (Bactrafuz-M Cream)	Each gm contains: Fusidic Acid 20mg (2% w/w) Mometasone Furoate 1mg (0.1% w/w)	1 gm	M/s Sirmour Remedies Pvt. Ltd. & M/s Lifestar Pharma Pvt. Ltd.	15.07

Read as

Sl. No.	Name of the Scheduled Formulation / Brand Name	Strength	Unit	Manufacturer & Marketing Company respectively	Retail Price (Rs.)
(1)	(2)	(3)	(4)	(5)	(6)
1.	Fusidic Acid + Mometasone Furoate (Bactrafuz-M Cream)	Each gm contains: Fusidic Acid 20mg (2% w/w) Mometasone Furoate 1mg (0.1% w/w)	1 gm	M/s Sirmour Remedies Pvt. Ltd. & M/s Lifestar Pharma Pvt. Ltd.	13.38

PN/179/47/2017/F

F. No. 8(47)/2017/D.P./NPPA-Div.-II

(BALJIT SINGH)  
Assistant Director